Zevra Therapeutics Inc 2026年季度报告

FORM 10-Q____________________________________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March31, 2026 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From _________ to _________ Commission File Number: 001-36913____________________________________________________________ Zevra Therapeutics, Inc.(Exact Name of Registrant as Specified in Its Charter) ____________________________________________________________ Delaware20-5894398 (I.R.S. Employer Identification No.) (State or Other Jurisdiction of Incorporation or Organization) 101 Federal Street, Boston, MA02110(Address of Principal Executive Offices)(Zip Code) (888) 958-1253(Registrant’s Telephone Number, Including Area Code) (Former Name, Former Address, and Former Fiscal Year if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smallerreporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ As of May1, 2026, the registrant had 59,115,084 shares of common stock outstanding. ZEVRA THERAPEUTICS, INC.FORM 10-Q SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, including the section entitled “Management’s Discussion and Analysis of Financial Conditionand Results of Operations,” contains forward-looking statements regarding future events and our future results that are subject to thesafe harbors created under the Securities Act of 1933, as amended (the “Securities Act”), and the Securities Exchange Act of 1934, asamended (the “Exchange Act”). Forward-looking statements relate to future events or our future financial performance. We generallyidentify forward-looking statements by terminology such as “may,” “will,” “would,” “should,” “expects,” “plans,” “anticipates,”“could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “assume,” “potential,” “continue”or other similar words or the negative of these terms. We have based these forward-looking statements largely on our currentexpectations about future events and financial trends that we believe may affect our business, financial condition and results ofoperations. The outcomes of the events described in these forward-looking statements are subject to risks, uncertainties and otherfactors described in “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December31, 2025, filed with theSEC on March9, 2026 (the “Annual Report on Form 10-K”), and elsewhere in this report. Accordingly, you should not place unduereliance upon these forward-looking statements. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materiallyfrom those anticipated in the forward-looking statements. Forward-looking statements contained in this report include, but are notlimited to, statements about: •our ability to commercialize and the timing of commercializing our products and product candidates, if approved;•the potential therapeutic benefits and effectiveness of our products and product candidates;•the progress of, timing of and expected amount of expenses associated with our commercialization, research, anddevelopment activities;•the size and characteristics of the markets that may be addressed by our products and product candidates;•the expected timing of clinical trials for our product candidates and the availability of data and results of those trials;•the progress of, outcome of and timing of any regulatory approval for any of our product candidates;•our expectations regarding fed